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Abstract
 
There is growing evidence that chemokines and their receptors regulate the movement and in-
teraction of antigen-presenting cells such as dendritic cells (DCs) and T cells. We tested the hy-
pothesis that the CC chemokine receptor (CCR)2 and CCR5 and the chemokine macrophage
 
inflammatory protein (MIP)-1
 
a
 
, a ligand for CCR5, influence DC migration and localization.
We found that deficiency of CCR2 but not CCR5 or MIP-1
 
a
 
 led to distinct defects in DC bi-
ology. Langerhans cell (skin DC) density in CCR2-null mice was normal, and their ability to
migrate into the dermis was intact; however, their migration to the draining lymph nodes was
markedly impaired. CCR2-null mice had lower numbers of DCs in the spleen, and this was
 
primarily due to a reduction in the CD8
 
a
 
1
 
 T helper cell type 1 (Th1)-inducing subset of DCs.
 
Additionally, there was a block in the 
 
Leishmania major 
 
infection–induced relocalization of
splenic DCs from the marginal zone to the T cell areas. We propose that these DC defects, in
conjunction with increased expression of B lymphocyte chemoattractant, a B cell–specific
 
chemokine, may collectively contribute to the striking B cell outgrowth and Th2 cytokine–biased
nonhealing phenotype that we observed in CCR2-deficient mice infected with 
 
L
 
.
 
 major
 
. This
disease phenotype in mice with an 
 
L
 
.
 
 major
 
–resistant genetic background but lacking CCR2 is
strikingly reminiscent of that observed typically in mice with an 
 
L
 
.
 
 major
 
–susceptible genetic
background. Thus, CCR2 is an important determinant of not only DC migration and localiza-
tion but also the development of protective cell-mediated immune responses to 
 
L
 
.
 
 major
 
.
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Introduction
 
It is in the lymphoid organs that T lymphocytes and APCs
such as B cells and dendritic cells (DCs)
 
1
 
 participate to gen-
erate adaptive immune responses (1–4). The trafficking of
these leukocytes is a tightly regulated multistep process.
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Abbreviations used in this paper: 
 
BLC, B lymphocyte chemoattractant;
CCR, CC chemokine receptor; DC, dendritic cell; LC, Langerhans cell;
MIP, macrophage inflammatory protein; MCP, monocyte chemoattrac-
 
tant protein; SLMA, soluble 
 
Leishmania
 
 
 
major
 
 antigen; TUNEL, TdT-medi-
ated dUTP nick end labeling. 
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However, the precise repertoire of signals that regulate
these processes is not fully understood (1–8). Clearly, a bet-
ter understanding of the determinants of leukocyte traffick-
ing and cell–cell localization might offer new opportunities
for therapeutic intervention to suppress or stimulate the
immune response.
Recently, a central function for various chemokines
and their receptors in lymphocyte and APC migration has
been identified (3–8). Based on in vitro chemotaxis and
chemokine receptor expression studies (5, 7, 9, 10) and the
in vivo studies of Tang and Cyster (11), a model for the
migration of DCs and Langerhans cells (LCs)—the skin
counterparts of DCs—has been proposed (3, 4, 8). In this
model, DC/LC migration is dependent on the selective re-
sponsiveness of immature and mature DCs/LCs to distinct
sets of chemokines, as well as the chemokine-induced
downregulation of the cognate chemokine receptor.
An important role for the chemokine system in DC/LC
migration and maintenance of the microanatomic environ-
ment of secondary lymphoid organs has also emerged (3, 4,
12–18). Mice deficient in CC chemokine receptor
(CCR)7 have impaired migration of lymphocytes and DCs
and profound morphological alterations in the architecture
of secondary lymphoid organs (13). A naturally occurring
mouse strain with a mutation designated as paucity of
lymph node T cells (
 
plt
 
) exhibits a defect in T cell homing,
LC migration, and localization of DCs to the T cell zones
of the spleen and lymph node (16). The genetic basis for
the 
 
plt
 
 phenotype is thought to be due to a defect in the
production of secondary lymphoid tissue chemokine (SLC)
(16). Targeted inactivation of CXC chemokine receptor
(CXCR)5 led to defects in the development of B cell folli-
cles and in B cell migration, indicating a major role for
CXCR5 and its ligand B lymphocyte chemoattractant
(BLC) in mediating compartmental homing of B lympho-
cytes (12, 18).
In light of the emerging importance of various members
of the chemokine system in DC biology, we tested the hy-
pothesis that the chemokine receptors CCR2 and CCR5
and the chemokine macrophage inflammatory protein
(MIP)-1
 
a
 
 influence DC migration and localization. Un-
derstanding the function of this chemokine and these two
receptors in DC biology and adaptive immune responses is
of additional interest because they play an important role in
HIV-1 pathogenesis (19). In contrast to mice deficient in
CCR5 or MIP-1
 
a
 
, CCR2-null mice had significantly im-
paired LC migration, reduced numbers of CD11c
 
1
 
 splenic
DCs (especially the Th1-inducing subset of DCs [20–22]),
and a block in the 
 
Leishmania major
 
 infection–induced relo-
calization of splenic DCs from the marginal zone to the T
cell areas.
In view of these findings, we used the cutaneous infec-
tion model of 
 
L
 
.
 
 major
 
, an intracellular parasite, to test the
hypothesis that the broad range of DC/LC abnormalities in
CCR2-deficient mice is associated with impaired adaptive
immune responses. This model offers several unique advan-
tages. First, 
 
L
 
.
 
 major
 
–infected LCs but not macrophages
play a central role in initiating primary Ag-specific T cell
 
responses (23, 24). This special function of LCs in experi-
mental cutaneous leishmaniasis is especially helpful in dif-
ferentiating the effects attributable to impaired LC migra-
tion versus the impaired monocyte migration observed in
CCR2-null mice (25–28). Second, several lines of investi-
gation have shown that susceptibility and resistance to 
 
L
 
.
 
major
 
 infection are associated with differential expansion of
Th1 and Th2 cell subsets (29). For example, C57BL/6
mice develop a parasite-specific expansion of IFN-
 
g
 
– and
IL-2–producing Th1 cells and are able to control infection
(healing phenotype). In contrast, BALB/c mice develop a
dominant expansion of IL-4–, IL-5–, and IL-10–producing
Th2 cells, marked B cell outgrowth (30, 31), sustained
neutrophilic inflammation at the site of skin infection (32),
and progressive disease (nonhealing phenotype).
Deficiency of CCR2 but not CCR5 or MIP-1
 
a
 
 in an 
 
L
 
.
 
major
 
–resistant genetic background led to a phenotype that
was strikingly reminiscent of that observed in 
 
L
 
.
 
 major
 
–sus-
ceptible BALB/c mice. Interestingly, the CCR2-deficient
mice appeared to be particularly primed for B cell expan-
sion, because in both the uninfected and infected state they
expressed significantly higher amounts of BLC, a B cell–
specific chemokine (18). Taken together, these findings
provide evidence for an important role for CCR2 in LC
migration, expression of Th1-inducing DC subsets, infec-
tion-induced relocalization of DCs, and potentially B cell
outgrowth. We propose that defects in these processes col-
lectively contribute to the striking Th2-biased nonhealing
phenotype observed in CCR2-deficient mice infected with
 
L
 
.
 
 major
 
.
 
Materials and Methods
 
Mice and Parasites.
 
The generation of CCR2
 
2
 
/
 
2
 
, CCR5
 
2
 
/
 
2
 
,
and MIP-1
 
a
 
2
 
/
 
2 
 
mice has been described previously (28, 33, 34).
Wild-type (
 
1
 
/
 
1
 
) and gene knockout mice were on an outbred
C57BL/6J 
 
3
 
 129/Ola genetic background (
 
n
 
 
 
. 
 
6 generations).
Mice were born and bred under specific pathogen-free condi-
tions. At 5–6 wk of age, mice were transferred from the Univer-
sity of Texas at Austin to the University of Texas Health Science
Center at San Antonio. The Institutional Animal Care and Use
Committee approved all protocols. 
 
L
 
.
 
 major
 
 clone VI (MHOM/
IL/80/Friedlin) was a gift of Dr. D.L. Sack (National Institutes of
Health, Bethesda, MD). The virulence of the 
 
L
 
.
 
 major
 
 strain was
maintained by propagating it in mice. Protocols similar to those
used to prepare soluble 
 
L
 
.
 
 major
 
 Ags (SLMAs) were used to make
soluble 
 
Leishmania donovani
 
 Ags (35). The intradermal route was
used to infect both ears with 2 
 
3
 
 10
 
6
 
 stationary phase of 
 
L
 
.
 
 major
 
promastigotes resuspended in 20 
 
m
 
l PBS. A dial-thickness gauge
caliper (Fred V. Fowler Co., Inc.) was used to measure ear thick-
ness at weekly intervals for 5 wk. The organisms were grown in a
biphasic medium containing blood agar (36), and the limiting di-
lution culture method was used to quantify parasite burden in the
ears, draining lymph nodes, and spleens (37).
 
Materials.
 
DMEM, RPMI 1640, medium 199, antibiotics,
FCS, Hepes, PBS, and trypsin were obtained from Life Technol-
ogies. All chemicals were from Sigma-Aldrich and Abs were from
BD PharMingen, unless otherwise stated.
 
Cells Migrating from Ear Skin Explants.
 
The protocols used
were those described by Larsen et al. (38) and Belkaid et al. (39, 
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40). In brief, the ears were dissected, rinsed in 70% ethanol with
vigorous shaking, and allowed to dry for 15 min. The ventral and
dorsal sheets were separated with a pair of fine forceps. The two
leaflets were transferred dermal side down for 24 or 72 h in a 10-cm
dish that contained culture medium (RPMI 1640 with 10%
FCS and 25 mM Hepes). Cell populations that spontaneously
emigrated out of the dermal layers were pooled. The loosely ad-
herent cells were recovered by incubating the dermal layers in
PBS containing 2 mg/ml glucose for 20 min at 37
 
8
 
C. The loosely
adherent cells and spontaneously migrating cells were pooled to-
gether, filtered through a 70-
 
m
 
m nylon cell strainer, washed with
PBS, and then stained. The LCs were identified as I-A
 
b
 
 bright
and DEC-205
 
1
 
. The neutrophils migrating from the skin ex-
plants were identified as cells that were Ly-6G bright and nega-
tive for I-A
 
b
 
. CD4
 
1
 
 T cells were identified as both CD3
 
1
 
 and
CD4
 
1
 
. The localization of LCs in the epidermal sheets was ana-
lyzed as described by Gunn et al. (16). The migration of epider-
mal LCs into the dermal lymphatics was analyzed as described
previously (41). In brief, after 72-h culture of ear explants, dermal
sheets were fixed in acetone for 30 min, rehydrated in PBS, and
incubated in 1:20 FITC-labeled anti–I-A
 
b
 
 mAb for 90 min at
room temperature. After washing in PBS, the dermal sheets were
mounted on microscope slides and evaluated by fluorescence mi-
croscopy.
 
Epidermis Cell Preparation.
 
The methods and protocols were
as described by Belkaid et al. (40). In brief, the ears were excised,
rinsed in 70% ethanol with vigorous shaking, and left to dry for
15 min. The dorsal and ventral sheets were separated and placed
in wells of 6-well plates containing 0.5% and 1% trypsin, respec-
tively, for 30 min at 37
 
8
 
C. The epidermis was separated from the
dermis and deposited on a 70-
 
m
 
m nylon cell strainer that was
placed in wells of a 6-well plate containing DMEM with 20%
FCS, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 0.05%
DNase. The nylon cell strainer was shaken gently for 2 min, and
the cells passing through were washed and incubated overnight at
37
 
8
 
C. Cells were stained with anti–DEC-205 mAb (NLDC-145;
Serotec) followed by PE-labeled anti–rat Ig polyclonal Ab and
FITC-labeled anti–I-A
 
b
 
 mAb, and were analyzed by FACSCali-
bur™ (Becton Dickinson).
 
LC Migration to Lymph Nodes.
 
The protocols described (42–
45) were used to track the migration of FITC
 
1
 
 LCs from the skin
to the draining lymph nodes. In brief, freshly prepared 5% FITC
in 1:1 acetone/dibutylphthalate was painted on both sides of the
ears (10 
 
m
 
l each) or on the abdomen (400 
 
m
 
l), and the draining
lymph nodes were collected. For FACS
 
®
 
 analysis, 24 h after the
ears were painted with FITC, the draining lymph nodes were dis-
sected, homogenized between the frosted ends of two micro-
scope slides, filtered through a nylon mesh, treated with red
blood cell lysing buffer, and washed with PBS. Cells were stained
initially with anti–DEC-205 mAb and then biotin-labeled anti–
rat IgG (Vector Laboratories). The cells were then stained with
CyChrome 5–labeled streptavidin (Amersham Pharmacia Bio-
tech) and PE-labeled anti–I-A
 
b
 
 mAb. Cells that were both
FITC
 
1
 
 and I-A
 
b
 
 bright were identified as LCs that had migrated
from the ear into the draining lymph nodes. In additional experi-
ments, after the abdomen was painted with FITC, the draining
lymph nodes were harvested 6, 24, 48, or 72 h later and frozen in
OCT compound (Sakura), and 5-
 
m
 
m cryostat sections were pre-
pared. FITC
 
1 
 
LCs in the sections of the draining lymph nodes
were examined by fluorescence microscopy (Olympus).
 
In Vitro Ag Presentation Activity.
 
For allogeneic mixed lym-
phocyte reactions, stimulator cells were metrizamide-enriched
LC fractions harvested from the draining lymph nodes 24 h after
 
the ears were painted with FITC. The metrizamide-enriched
DCs/LCs (43) were treated with 60 
 
m
 
g/ml of mitomycin C
(Calbiochem) for 30 min at 37
 
8C. Responder cells were CD31 T
cells purified from BALB/c spleens by a mouse T cell enrichment
column (R&D Systems). Responder T cells (2 3 105) were incu-
bated with varying concentrations of LCs for 96 h and pulsed
with [3H]thymidine (1 mCi/well; Amersham Pharmacia Biotech)
during the last 18 h of culture. Cultures were then harvested on
glass fiber filters (Skatron Instruments, Inc.) and counted by a
b-scintillation counter. For Ag-specific syngeneic proliferation
assays, DCs were purified from the spleen by the methods of
Leenen et al. (46), then incubated with 200 mg/ml of KLH for 20 h
at 378C and treated with 60 mg/ml of mitomycin C. Preparation
of Ag-primed lymph node T cells was as described previously
(47). T cells (2 3 105) were incubated with varying concentra-
tions of DCs for 4 d, and thymidine incorporation was deter-
mined.
Staining for DC Subtype in Spleen. Spleen cell suspensions were
prepared by collagenase digestion (48) and washed with 5 mM
EDTA-PBS. Cells were stained with FITC-labeled anti-CD8
mAb, PE-labeled anti-CD11c mAb, and allophycocyanin-labeled
anti-CD11b mAb in the presence of anti-CD16/CD32 mAb
(2.4G2) suspended in 5 mM EDTA-PBS.
Immunohistochemistry. Tissue samples of lymph nodes and
spleens were frozen in OCT, and 5-mm cryostat sections were
prepared. Sections were fixed in acetone for 10 min, air dried,
blocked with 0.1% BSA in tris-buffered saline for 10 min, and in-
cubated with unlabeled and biotin-labeled first mAb for 1 h.
Slides were then washed in tris-buffered saline, incubated with
horseradish peroxidase–labeled second Ab and streptavidin–alka-
line phosphatase–labeled second Ab for 1 h, and developed with
3,39-diaminobenzidine followed by Vector Blue or Vector Red
(Vector Laboratories) according to the manufacturer’s instruc-
tions. Similarly, double staining for apoptotic TdT-mediated
dUTP nick end labeling (TUNEL)1 cells was combined with
anti-B220 mAb or anti-CD11c mAb according to the manufac-
turer’s instructions (Boehringer). Each immunohistochemistry
photomicrograph is representative of multiple lymph node or
spleen sections derived from six to eight mice per group.
Histopathology. At necropsy, the ears were removed and
placed in neutral buffered 10% formalin. After adequate fixation,
the ears were embedded in paraffin. From each paraffin block, 5
mm–thick sections were cut and stained with hematoxylin and
eosin. Each section was evaluated for the nature of the cellular in-
filtrate, organisms, and necrosis. The pathologist (R.L. Reddick)
reviewing the histopathologic slides was blinded to the identity of
the source of the tissue sections.
Ag-specific Cytokine and Ig Production. Ag-specific IL-4 and
IFN-g production from spleen or lymph node cells was deter-
mined. Single cell suspensions (5 3 106/ml) were cultured with
or without 50 mg/ml of SLMA in 24-well plates. After 48 h of
culture, supernatants were harvested, and ELISA was used to de-
termine the cytokine levels. The methods for ELISA were as de-
scribed previously (33). The useful ranges for ELISA were 2.0–
125 pg/ml for IL-4, and 15.6-1,000 pg/ml for IFN-g.
Measurement of Serum Ig by ELISA. SLMA (10 mg/ml) was
coated onto 96-well plates. After blocking, serum from mice in-
fected for 5 wk was added to the well, serially diluted, and incu-
bated overnight at 48C. After washing, wells were incubated with
alkaline phosphatase–labeled anti–mouse Ig Ab, anti–mouse IgG1
mAb, anti–mouse IgG2a mAb, anti–mouse IgG3 mAb, or anti–
mouse IgE mAb, washed, then developed and measured as de-
scribed previously (33).208 Role of CCR2 in DC Migration and Cutaneous Leishmaniasis
Northern Blot Analysis. Total RNA (20 mg) from lymph
nodes of uninfected and infected wild-type and CCR2-null mice
was subjected to gel electrophoresis, transferred to Hybond N1
membranes (Amersham Pharmacia Biotech), and probed using
randomly primed 32P-labeled mouse cDNA probes. The follow-
ing primers were used for making PCR-derived probes for BLC
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH): BLC,
forward primer 59-CAGGCAGAATGAGGCTCAG-39 and
reverse primer 59-GGCAGCTCTTCTCTTACTCACTG-39;
and GAPDH, forward primer 59-TTGAAGGGTGGAGC-
CAAACG-39 and reverse primer 59-ACACATTGGGGGTAG-
GAACACG-39. For quantitation, films were scanned and ana-
lyzed by NIH Image software (v1.61). The BLC mRNA level
was corrected for the amount of RNA loaded by dividing the
BLC hybridization signal by the GAPDH signal. 
Statistical Analysis. Results are expressed as mean 6 SD. In
instances where the data were not normally distributed, they
were transformed into ranks and analyzed using analysis of vari-
ance to determine if there was an overall difference between the
groups. Tukey’s (see Fig. 5 and Fig. 6, A–H) or Dunnett’s (unin-
fected mice; see Fig. 1 C, Fig. 6 I, and Table I) posthoc tests were
used when an overall difference was observed. An unpaired two-
tailed t test was used for between-group analysis (infected mice;
see Fig. 8 D and Table I).
Results
Decreased Migration of LCs from Ear Skin Explants of
CCR2- and CCR5-null Mice. The ear skin explant model
(38, 40) and the model of FITC-induced LC migration
(42–45) are the two well-characterized complementary ap-
proaches that we used to test the hypothesis that mice defi-
cient in CCR2, CCR5, or MIP-a have impaired DC mi-
gration. The first model is an ex vivo model that allows for
the examination of LC migration from the skin epidermis
to the dermal lymphatics, whereas the latter model permits
an in vivo analysis of LC migration to the draining lymph
nodes. Previous studies have suggested that the migration
of LCs out of ear skin explants into the culture medium in
vitro may reflect, in part, their in vivo migratory capacity
(38).
The cumulative number of DEC-2051I-Ab1 (marker for
LC/DC and MHC class II, respectively) cells that migrated
out of the ear skin explants was greater at 72 h than at 24 h
in 1/1, CCR22/2, and CCR52/2 mice (Fig. 1 A). How-
ever, at both time points, the absolute number of LCs that
emigrated from CCR22/2 skin explants was 66–99% lower
than that of 1/1 mice (Fig. 1, A and B). Compared with
1/1 mice, the number of LCs that migrated from skin ex-
plants of CCR52/2 mice was also lower, but the defect was
not as prominent as that seen in CCR2-null mice. In con-
trast to CCR2- or CCR5-null mice, the migration of LCs
from the ear explants of MIP-1a–deficient mice was simi-
lar to that of 1/1 mice (data not shown).
These findings suggested that CCR2-null mice might
have a block in LC migration out of the dorsal ear skin.
However, an alternative explanation could be that LC mi-
gration is normal, and that these findings are secondary to
lower expression levels of DEC-205 in CCR2-null mice.
In this situation, the proportion of DEC-2052 but I-Ab1
cells should be higher in CCR2-null mice compared with
1/1 mice. However, this was not the case. The I-Ab1
DEC-2052 cells represented a small number of the migrat-
ing cells, and the knockout mice appeared to have similar
or lower numbers of I-Ab1DEC-2052 cells compared with
1/1 mice. The exact identity of the I-Ab1 but DEC-2052
cells is not clear, but they may represent mast cells (39). In
contrast to reduced numbers of LCs migrating out of the
skin explants, the number of neutrophils migrating out was
z2–4-fold higher in CCR2-null mice compared with 1/1
or CCR5-deficient mice (Fig. 1 A; data not shown). Com-
pared with 1/1 mice, the numbers of migrating CD41 T
cells was similar to (data not shown) or slightly higher (Fig.
1 A) in the CCR2-deficient mice.
Reduced LC migration in CCR2-deficient mice was
not due to a lower density of resident epidermal LCs (Fig.
1 C), and by immunohistochemistry, the number and in-
traepidermal distribution of LCs also appeared normal in
the different animal groups (data not shown). We excluded
the possibility that the reduced LC migration was due to a
block in the migration of LCs from the epidermis to the
dermis by staining the epidermal sheets of the ear skin ex-
plants that had been in culture for 72 h. The epidermal
layer in the skin explants of 1/1, CCR22/2, and
CCR52/2 mice contained only a few scattered I-Ab1 cells,
Figure 1. Migration of LCs out of ear skin explants of CCR22/2 and
CCR52/2 mice is reduced. (A) The absolute numbers of I-Ab1DEC-2051
(LCs) and I-Ab1DEC-2052 cells emigrating out of ear skin explants was
determined after 24 and 72 h of culture. The data for the 24- and 72-h
time points are from one of two and one of three representative experi-
ments, respectively. The migrating I-Ab2Ly-6G1 (neutrophils) and
CD31CD41 (CD41 T cells) cells were determined after 24 h of culture
(one of three representative experiments is shown). Data from skin ex-
plants of three to seven mice per group were pooled for analysis. The per-
centages of I-Ab1DEC-2051, I-Ab1DEC-2052, I-Ab2Ly-6G1, and
CD31CD41 cells among the total number of cells that emigrated are
shown in parentheses. (B) Representative FACS® profile showing a
marked decrease in I-Ab1DEC-2051 cells that migrated out of ear explants
of CCR22/2 and CCR52/2 mice. (C) The I-Ab1DEC-2051 cells (mean
number 6 SD) present in epidermal cell suspensions was determined by
flow cytometry. Epidermal cell suspensions were prepared from three
mice per group. Data are from one of two experiments with similar results.209 Sato et al.
suggesting that most of these cells had moved into the der-
mis (data not shown).
As there were lower numbers of CCR2- and CCR5-
deficient LCs migrating out, it would be expected that a
disproportionately larger number of these LCs would be
retained in the dermal layer. Indeed, this was the case.
Compared with 1/1 mice, the density of I-Ab–staining
cells in the dermal ear skin that had been in culture for 72 h
was greater in CCR22/2 and CCR52/2 mice (Fig. 2; data
not shown). Migrating DCs typically form cords within the
dermal lymphatics (38), and at higher magnifications, I-Ab
cells appeared to be distributed in a pattern consistent with
cords (Fig. 2). The cord formation was especially promi-
nent in CCR2-deficient mice (Fig. 2 B). However, addi-
tional studies are required to clarify whether these I-Ab–
staining cells distributed in the pattern of cords represent
cells accumulated within the dermal lymphatics or those
surrounding the lymphatics. Regardless of these two mech-
anistic possibilities, our findings suggest that mice deficient
in CCR2 have a defect in LC migration that, at least in this
ex vivo organ culture model of LC migration, is more sig-
nificant than that found in CCR5-null mice.
Impaired FITC-induced LC Migration to Draining Lymph
Nodes in CCR2-null Mice. We next used the well-estab-
lished FITC-based contact hypersensitivity model to deter-
mine whether lack of expression of CCR2 influenced sig-
nificantly the trafficking of LCs to the draining lymph
nodes in vivo (42–45). Hill et al. (42) have shown previ-
ously that after painting of the skin with FITC, there is a
rapid influx of FITC1 LCs into the draining lymph nodes
that peaks at 24 h; the levels of FITC-labeled DCs remain
elevated for another 2 d, and then decline to normal levels
by day 6.
We enumerated by fluorescence microscopy the number
of lymph node sections bearing FITC1 LCs at various time
points after painting of the skin with FITC (Fig. 3, A–O,
and data shown below). As early as 6 h after painting of the
skin with FITC, FITC1 LCs were found in z30% and
z6% of the draining lymph nodes of 1/1 (Fig. 3 A, and
data shown below) and CCR52/2 mice (Fig. 3 C, and data
shown below), respectively. These FITC1 cells were local-
ized primarily to the subcapsular region (Fig. 3, A and C).
In contrast, at this time point, lymph nodes containing
FITC1 LCs were not found in the CCR22/2 mice (Fig. 3
B). By 24 h, z65% and z75% of lymph nodes from 1/1
and CCR52/2 mice, respectively, contained FITC1 LCs
(Fig. 3, D and F, and data shown below). In contrast, in
CCR22/2 mice, the number of lymph node sections bear-
ing FITC1 LCs was substantially lower (z22%; Fig. 3 E,
and data shown below). In addition to this quantitative dif-
ference in the number of lymph node sections that con-
tained FITC1 LCs, there was a difference in the localiza-
tion of these LCs. At 24 h after FITC painting, the FITC1
LCs were dispersed throughout the lymph nodes of both
1/1 (Fig. 3, D and G) and CCR52/2 mice (Fig. 3, F and
I). However, in CCR22/2 mice, FITC1 LCs could be de-
tected only in or near the subcapsular region of the lymph
nodes (Fig. 3, E and H). At 48 h, nearly 80–100% of lymph
node sections from 1/1 and CCR52/2 mice versus 50%
of lymph node sections from CCR22/2 mice contained
FITC1 LCs. However, by 72 h, there was no difference in
either the number or the localization of FITC1 cells in any
of the groups of mice.
The finding of reduced LC migration in CCR2-null
mice was substantiated by flow cytometry analysis (Fig.
4). The number of I-Ab1DEC-2051, CD11c1CD8a1,
or CD11c1CD11b1 cells in non–FITC-sensitized mice
was similar in the different animal groups (data not
shown). Compared with 1/1 mice, the number of I-Ab–
brightFITC1 cells in the draining lymph nodes was de-
creased in CCR22/2 but not in CCR52/2 mice (Fig. 4 A).
The majority of the I-Ab–bright cells were DEC-2051
(Fig. 4 B) and not B lymphocytes (by B220 staining; data
not shown), indicating that most of the cells that stained
brightly for I-Ab were DCs. Additionally, compared with
1/1 mice, the number of FITC1I-Ab–brightDEC-2051
cells was lower in CCR2-null mice, but there was no dif-
ference in the numbers of FITC2I-Ab–brightDEC-2051
cells between 1/1 and CCR2-null mice (Fig. 4 C). The
proportion (mean percentage positive 6 SD) of LCs that
migrated to the draining lymph nodes in MIP-1a2/2 mice
(0.65 6 0.14) was similar to that in 1/1 mice (0.53 6
0.17).
Collectively, our findings indicate that mice lacking
CCR2 have a defect in LC migration. Contributing to
this defect, the migrating LCs may be disproportionately
retained in the subcapsular region, so that dispersion
throughout the lymph node is delayed. Because CCR2-
deficient mice have impaired macrophage recruitment (25–
28), a theoretical argument could be made that the reduced
migration of FITC-labeled LCs to the draining lymph
nodes is merely a reflection of impaired macrophage/
Figure 2. Disproportionately
higher numbers of I-Ab1 cells are
found in the dermal layers from
72-h skin explants of CCR2-
null mice. Dermal cords in ear
explants of (A) 1/1, (B)
CCR22/2, and (C) CCR52/2
mice. LCs (I-Ab1 cells) present in
the dermal layer of 72-h ear ex-
plants were examined by immu-
nofluorescence (A–C; original
magnification:  3200).210 Role of CCR2 in DC Migration and Cutaneous Leishmaniasis
monocyte recruitment. Furthermore, a case could be made
that an additional confounding factor is the observation
that monocytes may differentiate into DCs during migra-
tion into the lymphatic vessels (49). However, these con-
founding factors are unlikely to account for our findings of
decreased LC migration in CCR2-null mice, as previous
studies have clearly demonstrated that after FITC sensitiza-
tion, the FITC1 cells in the lymph node cells are derived
entirely from the LC population (49, 50).
Reduced Th1-inducing DCs and Impaired Infection-induced
Relocalization of CD11c1 Cells in the Spleens of CCR2-defi-
cient Mice. Characterization of splenic DC subpopulations
by phenotypic, functional, and histological parameters has
identified two major DC subsets in the spleen and has
shown that these DC subsets reside in distinct microenvi-
ronments (20, 22). By immunohistochemistry, CCR22/2
mice had reduced numbers of CD11c1 cells compared
with 1/1 and CCR5-null mice (data not shown). These
findings were confirmed by three-color flow cytometry
(Table I), and the maximum decrease was in the subpopu-
lation of DCs whose staining pattern was CD11c1
CD8a1CD11b2 (Table I). Although the mean number of
CD11c1CD8a2CD11b1–staining DCs also appeared lower
in CCR2-null mice, these differences were not statistically
significant.
There is evidence that after activation of splenic DCs in
vivo, such as after administration of LPS, there is conver-
sion of immature to mature DCs and relocalization of mar-
ginal zone DCs into the T cell areas (51). Activation of
DCs after an infection is a more physiological model for
examining this activation-induced relocalization of DCs,
and would also place the interpretation of the immune re-
sponses observed in CCR2-null mice after infection with
L. major in a more appropriate context. By three-color flow
Figure 3. Reduced migration of LCs to draining lymph nodes in
CCR2-deficient mice after contact sensitization with FITC. (A–O) Time
course of migration of FITC1 LCs into lymph nodes. (A–C) 6, (D–I) 24,
(J–L) 48, and (M–O) 72 h after painting of abdomen of 1/1, CCR22/2,
and CCR52/2 mice with FITC, the draining lymph nodes were collected
and examined by fluorescence microscopy. Representative lymph node
sections at these time points are shown. The original magnification shown
is 3400 except in D–F, where it is 3100. A–C, D, F, and H are represen-
tative photomicrographs from the edge of the lymph node, whereas E de-
picts an entire lymph node. G, I, and J–O are from the center of the lymph
nodes. The number of lymph node sections that contain FITC1 LCs per
total number of draining lymph node sections examined is shown below
A–O (n 5 3 mice per group per time point). A section with even a single
FITC1 cell was considered positive. Thus, for example, by this stringent
criteria, in the CCR22/2 mice at 6 h, no lymph node sections contained
any FITC1 LCs, whereas 4 of 18 sections contained FITC1 LCs at 24 h.
A–C show localization of FITC1 LCs to the periphery of the lymph nodes
in A and C, but not in B. In E and H, a few FITC1 LCs could be detected
only in the periphery of the lymph node sections, whereas in D, F, G, I,
and J–O, FITC1 LCs were found dispersed throughout the lymph node
sections. Note, the edges of the lymph nodes contain free FITC.
Figure 4. Impaired migration of LCs to the draining lymph nodes in
CCR22/2 mice. (A) The ears of 1/1, CCR22/2, and CCR52/2 mice
were painted with FITC, and 24 h later, cells from two cervical lymph
nodes were pooled and stained with PE-labeled anti–I-Ab mAb. Three
animals per group were analyzed. Representative FACS® profile showing
a reduction in the absolute number (and proportion) of FITC1I-Ab–
bright cells that migrated from the ear in CCR22/2 mice. The data are
from one of three representative experiments. (B) Representative FACS®
profile showing that most of the I-Ab–bright cells found in the upper-
right quadrants in A also stain positive for DEC-205, suggesting that they
represent LCs. The FACS® profile is from 1/1 mice. (C) Reduced mi-
gration of DEC-2051I-Ab1FITC1 cells in CCR2-null mice. Data were
obtained by three-color cytometry analysis and are from two 1/1 and
three CCR2-null mice.211 Sato et al.
cytometry, 7-d–infected CCR2-null mice had lower num-
bers of CD11c1CD8a1CD11b2 and CD11c2CD8a2
CD11b1 DC subsets compared with infected 1/1 mice
(Table I). Analagous to the findings in LPS-treated mice
(51), by immunohistochemistry we found that infected 1/1
mice had increased numbers of CD11c1 cells in the T cell
areas compared with uninfected 1/1 mice (data not
shown). However, compared with infected 1/1 mice,
there was a paucity of CD11c1 cells in the periarteriolar
sheaths of the infected CCR2-null mice. Taken together,
our data suggest that CCR2 is an important determinant
for the localization of CD8a1 splenic DCs and the activa-
tion-induced movement of DCs into the T cell areas of the
spleen.
Normal Ag-presenting Capacity of LCs/DCs in CCR22/2
and CCR52/2 Mice. To determine whether LCs in
CCR22/2 mice were functionally active, DCs were puri-
fied from draining lymph nodes of FITC-sensitized mice
and examined for their capacity to activate allogeneic T
cells. Allogeneic BALB/c T cells were isolated and mixed
with  1/1, CCR22/2, or CCR52/2 DCs (data not
shown). DCs isolated from CCR22/2 and CCR52/2 mice
were similar to those from 1/1 mice in their ability to
stimulate allogeneic T cells. To analyze further the Ag-pre-
senting capacity of DCs from knockout mice, KLH-pulsed
spleen DCs from 1/1, CCR22/2, or CCR52/2 mice
were incubated with purified CD31 T cells derived from
1/1 mice immunized with KLH. KLH-pulsed spleen
DCs isolated from 1/1, CCR22/2, or CCR52/2 mice
were equally effective in stimulating Ag-specific prolifera-
tion of CD31 T cells (data not shown). Similar results were
also obtained by using KLH-pulsed bone marrow–derived
DCs in Ag-specific syngeneic proliferation assays (data not
shown).
CCR2-deficient Mice Are Susceptible to L. major Infection
and Develop a Predominant Th2-like Response. The contri-
bution of the aforementioned defects in DC migration and
localization in CCR2-null mice to the development of a
protective cell-mediated immune response to L. major in-
fection was next examined. The genetic background of the
wild-type and knockout mice used in these studies is com-
posed of two resistant strains, C57BL/6 and 129/J (52).
Control animals and mice deficient in CCR5 or MIP-1a
retained the L. major–resistant phenotype as demonstrated
by mild, self-resolving ear swelling (Fig. 5 A). In contrast,
CCR2-null mice failed to control L. major, and the ear
Table I. CD11c1 DC Subsets in 1/1, CCR22/2, and CCR52/2 Mice
CD11c1CD8a1CD11b2 CD11c1CD8a2CD11b1
Genotype Percentage positive Number Percentage positive Number
(3106)( 3106)
Uninfected 1/1 1.04 6 0.19 1.48 6 0.53 2.44 6 0.89 3.53 6 1.86
CCR22/2 0.49 6 0.10* 0.72 6 0.20 1.58 6 0.17 2.31 6 0.19
CCR52/2 0.92 6 0.13 1.52 6 0.17 2.77 6 0.33 4.60 6 0.54
Infected 1/1 1.22 6 0.04 1.22 6 0.12 1.31 6 0.22 1.30 6 0.08
CCR22/2 0.79 6 0.16‡ 0.51 6 0.10* 0.67 6 0.23‡ 0.43 6 0.14*
Three-color flow cytometry analysis was used to determine the proportion and absolute numbers (mean 6 SD) of CD11c1CD8a2CD11b1 DCs in 
spleen cell suspensions.
*P , 0.05, difference from 1/1 mice.
‡P , 0.01, difference from 1/1 mice.
Figure 5. CCR22/2 mice
showed marked sensitivity to L.
major infection. (A) Thickness of
the ears of wild-type (1/1; s),
CCR22/2 ( d), CCR52/2 ( m),
or MIP-1a2/2 (j) mice after in-
tradermal inoculation of L. major.
Results are the mean 6 SD for
10 mice (2 d and 1 wk) or 5
mice (2, 3, 4, and 5 wk). (B–D)
Parasite burden in the ears,
draining lymph nodes, and
spleens. Results are the mean 6
SD for five mice, and are from
one of two representative exper-
iments.  *P  , 0.05 and **P ,
0.01, difference from 1/1 mice.212 Role of CCR2 in DC Migration and Cutaneous Leishmaniasis
thickness continued to increase during the course of infec-
tion (Fig. 5 A). 1 and 3 wk after infection, there was no
significant difference in the parasite burden between the
knockout and 1/1 mice (data not shown). However, at 5
wk after infection, the highest parasite burden in the ears,
draining lymph nodes, and spleens was in mice deficient in
CCR2 (Fig. 5, B–D). Parasites could be detected in 90% of
the infected spleens of CCR22/2 mice. In contrast, none
of the 1/1 mice and only 30% of CCR52/2 or MIP-1a2/2
mice had parasites in the spleen. Thus, progression to dis-
ease beyond the draining lymph nodes (i.e., visceralization
to other organs) was greatest in mice lacking CCR2.
To assess the Th effector cell phenotype in the infected
animals, in vitro Ag-specific cytokine production was mea-
sured 1 and 5 wk after infection (Fig. 6, A–H). Previous
studies have shown that the early development of Th2 (IL-
4) but lower Th1 (IFN-g) responses underlie susceptibility
to infection (29). Concordant with these observations, 1
wk after infection, the Ag-specific production of IFN-g in
the draining lymph nodes and spleens of CCR2-null mice
was lower compared with 1/1 mice (Fig. 6, C and D).
Conversely, Ag-specific IL-4 production was higher in the
draining lymph nodes of CCR2-null mice (Fig. 6 A). At
later stages of infection, CCR2-null mice produced high
levels of both IL-4 and IFN-g (Fig. 6, E–H). Previous
studies have demonstrated that although a Th1 response is
sufficient to protect against cutaneous leishmaniasis, the in-
duction of a simultaneous Th2 response abrogates the Th1
effector function (29, 53).
In contrast to CCR2-null mice, a Th2-biased cytokine
profile was not evident in mice deficient in either CCR5
or MIP-1a. CCR5-null mice had higher levels of IFN-g
in the spleen and lymph nodes 1 and 5 wk after infection
(Fig. 6, G and H). At 5 wk after infection, CCR5-null
mice produced significantly lower levels of Ag-specific IL-4
in the spleen (Fig. 6 F).
Additional evidence for a dominant Th2 phenotype in
CCR2-null mice came from the finding that 5 wk after in-
fection, the Ag-specific Ig and IgG1 levels were signifi-
cantly higher in the CCR22/2 mice compared with 1/1,
CCR52/2, or MIP-1a2/2 mice (Fig. 6 I). The levels of
IgG2a, an Ig typically associated with Th1-biased re-
sponses, were similar in the different animal groups (Fig. 6
I). Ag-specific IgG3 and IgE were not detectable (data not
shown). However, total IgE levels were z11-fold higher
in CCR2-deficient mice compared with wild-type mice
(data not shown).
Marked Neutrophilic Inflammation in CCR22/2 Mice Infected
with L. major. Persistent neutrophilic inflammation in the
infected ears is one of the hallmarks of the pathological
changes that occur in mice susceptible to experimental cu-
taneous leishmaniasis (32). Concordant with these observa-
tions, we found that the ears of 6-wk–infected CCR22/2
mice were remarkable for a prominent neutrophilic infil-
trate with areas of necrosis, whereas the ears of infected 1/1,
CCR52/2, or MIP-1a2/2 mice had scattered infiltrating
monocytes and fibroblasts (Fig. 7, A and B). Notably, by
histology, neutrophils comprised z80% of the total inflam-
matory infiltrate in CCR22/2 mice. We took advantage of
the ear skin explant model and flow cytometry to quantify
the magnitude and kinetics of neutrophil recruitment in
CCR2-null mice. At both 1 and 7 d after infection, neu-
trophils comprised .70% of the total number of cells in the
infected ears of CCR2-null mice (Fig. 7 B). In contrast, in
wild-type and CCR5-null mice, neutrophils comprised
z40–60% of all cells in the infected ears 1 d after infection,
and ,20% at day 7 after infection (Fig. 7 B). Taken to-
gether, these findings suggest that the inflammatory re-
sponse in CCR2-null mice on a genetically resistant back-
ground is remarkably reminiscent of the acute inflammatory
response seen during L. major infection in susceptible
BALB/c mice (32).
Enhanced B Cell Outgrowth and Increased BLC mRNA Ex-
pression in CCR2-deficient Mice. Previous studies have in-
dicated that an outgrowth of B cells during the acute phase
of L. major infection correlates with a Th2-type dominance
(30). 1 wk after infection with L. major, compared with 1/1
mice, in sections stained for B2201 cells the B cell follicles
Figure 6. Ag-specific production of IL-4 and IFN-g by lymph node
and spleen cells after 1 wk (A–D) or 5 wk (E–H) of L. major infection in
wild-type (1/1; s), CCR22/2 (d), CCR52/2 (m), or MIP-1a2/2 (j)
mice. Horizontal lines in each panel indicate the mean cytokine produc-
tion level in wild-type mice. Each symbol represents the Ag-specific cy-
tokine levels produced from a single mouse. One of three representative
experiments is shown. I shows L. major–specific total Igs, IgG1, and
IgG2a levels in serum of 1/1, CCR22/2, CCR52/2, and MIP-1a2/2
mice after 5 wk of infection. Data represent OD obtained after a 400-fold
dilution of the serum, and the data are expressed as mean 6 SD. (n 5 five
mice per group). One of two representative experiments is shown. †P ,
0.05 and ††P , 0.01, difference from 1/1 mice.213 Sato et al.
in the draining lymph nodes in CCR22/2 mice were very
enlarged (data not shown). Double labeling for B220 and
apoptotic cells (TUNEL technique; Fig 8, A and B)
showed a marked increase in TUNEL1 cells in the B cell
areas, suggestive of increased B cell proliferation.
Because the B cell outgrowth was so prominent in
CCR2-null mice, we tested the possibility that this may be
due to higher expression of BLC, a B cell–specific
chemokine (15, 17). Stromal cells, including follicular DCs
found in the B cell regions of all secondary lymphoid tissue,
produce BLC (15, 54), and several factors have been shown
to influence the expression of BLC (15, 17, 55). CCR2-
deficient mice appeared to be primed for enhanced B cell
outgrowth after infection, as compared with 1/1 mice,
the lymph nodes derived from 1-d L. major–infected
CCR2-deficient mice expressed significantly higher amounts
of BLC mRNA (Fig. 8, C and D). Interestingly, lymph
nodes of uninfected CCR2-null mice also expressed higher
levels of BLC mRNA (Fig. 8 C). Studies are underway to
determine whether signaling via CCR2 negatively regu-
lates BLC expression directly or indirectly (i.e., by inhibit-
ing the maturation of BLC-expressing stromal cells, such as
follicular DCs).
Discussion
The trafficking events that bring together T cells, B lym-
phocytes, and DCs—the major participants of cellular and
humoral immune responses—form a tightly orchestrated
and complex process for which a key role for the chemo-
kine system has emerged (3–8). In this study, we demon-
strate that CCR2 is an important determinant of DC/LC
migration and localization, especially in the localization of
CD8a Th1-inducing splenic DCs, and is required to gen-
erate protective cell-mediated immune responses to L. ma-
jor infection. In contrast, major defects in DC migration or
localization or in host responses to L. major infection were
not observed in mice that have an identical genetic back-
Figure 7. Marked neutrophilic inflammation in mice deficient in
CCR2. (A) The histopathological sections (hematoxylin and eosin; origi-
nal magnification: 3400) are from mice infected for 5 wk with L. major.
Abundant organisms admixed with areas of necrosis, karryohectic cellular
fragments, and polymorphonuclear leukocytes including eosinophils were
found in CCR22/2 mice. In contrast, the ears from 1/1, CCR52/2,
and MIP-1a2/2 mice had fibroblasts with scattered cellular infiltrates that
consisted of mononuclear cells, epitheloid histiocytes, lymphocytes, and
plasmacytoid cells. Necrosis was absent in these three groups of mice. (B)
Marked recruitment of neutrophils to the ears of CCR2-null mice after
intradermal infection with L. major. 1 and 7 d after L. major infection, the
cells that emigrated from ear skin explants were stained with FITC-labeled
anti-I-Ab mAb and PE-labeled anti–Ly-6G mAb. Percentage (left) and
total number (right) of neutrophils (Ly-6G brightI-Ab2) among all cells
that emigrated from skin explants of 1/1 ( s), CCR22/2 ( d), and
CCR52/2 (n) mice are shown. Results from one of three representative
experiments are shown.
Figure 8. Enhanced B cell outgrowth and increased BLC mRNA ex-
pression in the lymph nodes of L. major–infected CCR2-deficient mice.
(A and B) Lymph nodes from 7 d–infected 1/1 and CCR22/2 mice
were stained with anti-B220 mAb (brown) and TUNEL (blue) (original
magnification: 3100). (C and D) Increased BLC mRNA expression in
CCR2-null mice. BLC mRNA expression was determined in uninfected
cervical lymph nodes or in the draining cervical lymph nodes after 1 d of
L. major infection in wild-type and CCR2-null mice. (C) 20 mg of total
RNA was purified, and Northern blots were hybridized with a radiola-
beled BLC-specific probe. The autoradiographs were obtained after 4 d
(BLC) or 1 d (GAPDH) of exposure. (D) Relative BLC mRNA levels
were determined from the mRNA blots of the infected animals shown in
A. Data from individual mice are shown (s,  1/1 mice) and (d,
CCR22/2 mice), and the bar represents the mean. Data from one of two
representative experiments are shown.214 Role of CCR2 in DC Migration and Cutaneous Leishmaniasis
ground but are deficient in CCR5 or MIP-1a. The con-
current analysis of three knockout mice on identical L. ma-
jor–resistant genetic backgrounds also affords some insights
into the issue of redundancy versus specificity of distinct
chemokine receptor–ligand pairs. Despite sharing overlap-
ping ligand/agonist profiles (7, 56), the in vivo function of
CCR2 cannot be replaced by CCR5, whereas it would ap-
pear that the converse is not true, indicating that in the ge-
netic background tested, CCR2 has nonredundant proper-
ties with regard to Th1/Th2 balance in experimental
cutaneous leishmaniasis.
Where do CCR2 and CCR5 fit into the proposed com-
plex model of LC/DC navigation (3, 4, 8)? Because con-
tact sensitization induced by FITC skin painting is known
to induce DC maturation and mobilization (49, 50), and
because CCR2 and CCR5 are thought to be involved pri-
marily in the trafficking of immature DCs, the finding of
marked impairment of LC migration in CCR2-deficient
mice was unanticipated. How then does one reconcile
these findings in the context of the proposed model of LC/
DC migration? There are several lines of evidence to sug-
gest that CCR2 expression influences the migration of
both immature and mature LCs. First, in addition to being
an inducible or “inflammatory” chemokine, monocyte
chemoattractant protein (MCP)-1 is constitutively ex-
pressed by many tissues (57). Indeed, at least in human
DCs, MCP-1 is expressed by immature DCs, and its ex-
pression is strongly upregulated in mature DCs (10). Thus,
because CCR2 is the only known high-affinity receptor for
MCP-1, the CCR2–MCP-1 axis may influence both
phases of LC migration. Second, although a switch in
chemokine receptor profile during DC maturation is
clearly an important determinant in DC migration, studies
with in vitro–derived human or murine DCs indicate that
this switch may not be an all-or-none phenomenon. In in
vitro expression studies, murine CCR2 is constitutively ex-
pressed on control/immature DCs, and although after ex-
posure to TNF-a the levels of CCR2 mRNA decline sig-
nificantly, CCR2 expression on activated DCs remains
detectable (9). On the other hand, in these experiments,
murine CCR5 expression on activated DCs was not de-
tectable (9). Thus, the continued expression of murine
CCR2 but not CCR5 on mature/activated DCs could in-
fluence the migration of maturing murine DCs and is con-
sistent with our in vivo findings of reduced migration of
activated LCs to the draining lymph nodes. Additionally,
the changes in receptor profiles observed in in vitro–derived
DCs (CD341 stem cell– or bone marrow–derived DCs)
may not accurately mirror the changes that occur on native
DCs in vivo. Also, the efficiency with which this switch in
receptor expression occurs in response to activation may be
highly dependent on the stimulus (9, 10), and thus the re-
sults found after in vitro and in vivo DC activation are un-
likely to be the same.
Defects in DC biology in CCR2-deficient mice were
not restricted to a decrease in LC migration. In contrast to
the fairly global defect in DC localization in the spleen and
lymph nodes of mice lacking expression of the second-
ary lymphoid tissue chemokine (16), DC localization in
CCR2-deficient mice appeared to be relatively specific to
the CD8a1 lineage of DCs in the spleen. The finding of
reduced numbers of CD8a1 DCs is especially intriguing
because recent studies suggest that the nature of the DC
that presents Ags to naive T cells may dictate the class se-
lection (Th1/Th2) of the adaptive immune response (20–
22). CD8a1 DCs have been shown to drive the develop-
ment of Th1-type immune responses required to control
intracellular infections, whereas CD8a2 DCs induce the
differentiation of Th2-type responses that are important in
the control of extracellular infections (21). Additionally, re-
striction of the DC defects to LC migration and localiza-
tion of CD8a1 DCs is interesting in the context of recent
studies suggesting that LCs also belong to the CD8a1 DC
lineage (58).
Our studies in knockout mice on an L. major–resistant
genetic background provide insights into the role of
CCR2, CCR5, and MIP-1a in cure versus susceptibility
to experimental cutaneous leishmaniasis. Studies of infec-
tion with L. major have established a paradigm for the role
of different T helper subsets during infection (29). Early
production of IFN-g and IL-12 is responsible for Th1 de-
velopment and disease resistance, whereas an early IL-4 re-
sponse induces Th2 cell development in susceptible mice.
Susceptible BALB/c mice permit a rapid dissemination of
L. major parasites to visceral organs within the first 10–24 h
of infection, whereas in resistant strains such as C57BL/6,
the parasites are restricted to the site of infection and the
draining lymph node. There were striking similarities in
the disease expression of L. major infection in BALB/c
mice and CCR2-deficient mice. This included progressive
and disseminated infection, presence of high IL-4 levels
during the early and later phases of the immune responses,
higher production of IgG1, prominent local neutrophilic
inflammation, and enhanced B cell outgrowth that may be
related to increased BLC expression. In contrast, mice defi-
cient in CCR5 or MIP-1a had phenotypes similar to those
of the L. major–resistant genetic background mice.
In a recent report, Gu et al. (59) reported that mice lack-
ing MCP-1 have impaired Th2 responses and resist L. major
infection. These findings are the opposite of those that we
observed in L. major–infected CCR2-deficient mice. Sev-
eral explanations can be invoked to explain these contrast-
ing and paradoxical findings, including the possibility that
MCP-3 and MCP-5, two additional high-affinity ligands
for CCR2, might induce Th1 polarization in MCP-1–
deficient mice. Also, differences in the L. major disease phe-
notype in other ligand–receptor pairs have been noted (60).
However, before making firm conclusions about the con-
trasting functions of MCP-1 and CCR2, several important
caveats should be considered. First, some of the compari-
sons between MCP-1 and CCR2 knockout mice are in
contrasting genetic backgrounds. For example, the L. major
infection studies reported by Gu et al. (59) were in the sus-
ceptible background (BALB/c), whereas our studies were
in the resistant background (C57BL/6 3 129). Several
studies have documented that the same mutation can have215 Sato et al.
markedly different phenotypes when placed on different
genetic backgrounds (61, 62). This variation is due to dif-
ferent alleles at modifying loci in various inbred strains.
Second, extensive studies in mice deficient for IL-4 or its
receptor (IL-4Ra) have shown that the disease outcomes
to L. major infection are heavily dependent on the parasite
substrain (63, and references therein). Thus, to resolve the
contrasting L. major phenotype in MCP-1– and CCR2-defi-
cient mice, it will be necessary to conduct concurrent stud-
ies of these two knockouts on similar genetic backgrounds
using identical L. major strains.
Can a direct connection be made between the Th2-
biased L. major–susceptible phenotype in CCR2-null mice
and the DC defects? Given the broad array of complex DC
defects, providing experimental evidence that any one of
these DC defects is directly responsible for the susceptible
phenotype is a challenging task. It is more likely that in
CCR2-null mice, the sum of these DC defects in conjunc-
tion with enhanced susceptibility to B cell expansion col-
lectively contribute to this phenotype. Nevertheless, based
on our current findings, two possible scenarios can be en-
visaged by which the observed defects can affect an L. major
Ag–specific T cell–dependent response, and consequently
susceptibility to infection.
The first scenario ties in the potential immunological
consequences of the observed defects at the level of lymph
node, i.e., impaired Ag presentation due to inadequate mi-
gration of Ag-bearing LCs and enhanced B cell outgrowth.
For mature DCs to function in an immunogenic manner,
it is clear that they need to interact rapidly with Ag-spe-
cific T cells. In an elegant study, Inguilli et al. (64) demon-
strated that there is a limited window of time during which
Ag-loaded DCs interact with T cells. Ag (OVA)-bearing
DCs were found to interact with naive Ag-specific T cells
within the T cell–rich regions of lymph nodes during the
first 24 h after injection of ex vivo Ag-pulsed DCs, and
that 48 h after injection, Ag-pulsed DCs disappeared from
the lymph nodes (64). It was during this critical 0–24-h
period that LCs from CCR2-null mice had the greatest
impairment in migration, and it is known that the factors
that influence Th cell differentiation after L. major infec-
tion are operative within the first hours or days of infection
(65, 66). Studies in other experimental systems have also
shown that the early events in the differentiation of naive
CD41 T cells determine the nature of cytokines produced,
and thus influence Th1/Th2 balance (67). Concurrent
with this defect, we observed that CCR2-null mice are
primed for increased B cell outgrowth. This observation is
important in the context that, in general, macrophages and
DCs preferentially induce IFN-g and IL-2 secretion,
whereas B cells are more efficient in activating IL-4 pro-
duction (68). Additionally, Palanivel et al. (30) demon-
strated that B cell outgrowth and Ag-specific production of
Th2 cytokines correlate with Th2 dominance. Thus, in the
context of these observations, it is not inconceivable that
the combination of impaired Ag presentation due to re-
duced migration of Leishmania Ag-loaded DCs to the
draining lymph nodes and the propensity for increased B
cell expansion could lead to a skewed Th2 phenotype in
CCR2-null mice.
In the second scenario, the altered splenic microenviron-
ment in naive, uninfected CCR2-null mice (i.e., reduced
Th1-inducing DCs in the T cell areas) and impaired infec-
tion-induced relocalization of DCs from the marginal zone
to the T cell areas also provide another connection to the
Th2-biased L. major–susceptible phenotype. Interestingly, 1
wk after infection, the Ag-specific production of IFN-g
was lower in the spleens of CCR2-null mice, and this in-
ability to generate a Th1 response may be attributable, in
part, to reduced numbers of Th1-inducing splenic DCs.
The possibility of these alterations in skewing the Th bal-
ance is also highlighted by the observation that Th1 and
Th2 cells home to distinct microenvironments of the
spleen, and that this unique cellular migration pattern may
be due to the differential expression patterns of chemokine
receptors (69).
In summary, the findings presented herein demonstrate
that CCR2 plays a key role in the migration of DCs/LCs
in vivo, as well as DC/LC localization. The preferential
decrease in CD8a, Th1-inducing splenic DCs, and the in-
fection-induced block in DC relocalization would suggest
that CCR2, in addition to CCR7, is important in main-
taining functional microenvironments in secondary lym-
phoid organs. Regardless of whether these DC defects con-
tribute directly or indirectly to the striking Th2-biased
phenotype, our studies demonstrate a central role for
CCR2 in regulating Th1/Th2 balance in experimental cu-
taneous leishmaniasis in mice that are normally resistant to
this infection.
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